BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation
Reuters
Jul 28
<a href="https://laohu8.com/S/BLFS">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation
BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.